{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:30:45Z","timestamp":1780504245908,"version":"3.54.1"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:p>\n            Fostemsavir is a prodrug of temsavir, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4\n            <jats:sup>+<\/jats:sup>\n            T cells with demonstrated efficacy in phase 2 and 3. Temsavir is a P-glycoprotein and breast cancer resistance protein (BCRP) substrate; its metabolism is mediated by esterase and CYP3A4 enzymes.\n          <\/jats:p>","DOI":"10.1128\/aac.02251-21","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:00:37Z","timestamp":1647954037000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir\/Cobicistat, or Darunavir\/Ritonavir with or without Etravirine in Healthy Participants"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-381X","authenticated-orcid":true,"given":"Katy","family":"Moore","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-5796","authenticated-orcid":true,"given":"Nilay","family":"Thakkar","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Magee","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sevinsky","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Hopewell, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blisse","family":"Vakkalagadda","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Hopewell, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lubin","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Hopewell, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Llamoso","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ackerman","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Branford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.472"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823fe66b"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097482"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/prot.24726"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23476"},{"key":"e_1_3_3_7_2","volume-title":"Abstr 19th International Workshop on Clinical Pharmacology of Antiretroviral Therapy","author":"Gorycki P","year":"2018","unstructured":"Gorycki P, Magee M, Ackerman P, Barros A, Jr, Burrell R, Gandhi Y, Llamoso C, Moore K. 2018. Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. Abstr 19th International Workshop on Clinical Pharmacology of Antiretroviral Therapy, abstr 42."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04914-14"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00177-0"},{"key":"e_1_3_3_10_2","unstructured":"DeJesus E Martins M Stoehr A Andrade-Villanueva J Zakharova N Stock DA Llamoso C Joshi SR Hanna GJ Lataillade M. 2016. Attachment inhibitor prodrug BMS-663068 in ARV-experienced subjects: week 96 analysis. Abstr 23rd Conference on Retroviruses and Opportunistic Infections abstr 472."},{"key":"e_1_3_3_11_2","unstructured":"Llamoso C Bogner JR Afonina L Le\u00f3n M Yakovlev A Stock DA Joshi SR Hanna GJ Lataillade M. 2016. HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 safety analysis. Abstr HIV Drug Therapy Glasgow 2016 abstr O335B."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_3_3_13_2","unstructured":"Janssen-Cilag. 2020. Prezista: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000707\/WC500041756.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_14_2","unstructured":"Janssen-Cilag. 2020. Intelence: summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000900\/WC500034180.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_15_2","unstructured":"Gilead Sciences. 2020. Tybost. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002572\/WC500153014.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_16_2","unstructured":"Gilead Sciences. 2020. Genvoya. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004042\/WC500197861.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_17_2","unstructured":"Gilead Sciences. 2020. Stribild. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002574\/WC500144272.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_18_2","unstructured":"AbbVie. 2021. Norvir. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000127\/WC500028728.pdf. Accessed 12 April 2021."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01046-10"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02503-15"},{"key":"e_1_3_3_21_2","unstructured":"Parasrampuria R Goyal N Moore K Ackerman P Llamoso CC Barker K Magee M. 2020. Fostemsavir exposure-response relationships in treatment experienced HIV patients. Abstr 27th Conference on Retroviruses and Opportunistic Infections abstr 463."},{"key":"e_1_3_3_22_2","unstructured":"Hruska MW Savant IA Anderson JA Shah V Chang I Adamczyk R Furlong M Hanna GJ Bertz R Zhu L. 2014. Thorough QT\/QTc trial to evaluate the effect of the HIV-1 attachment inhibitor BMS-626529 administered as its prodrug BMS-663068 on QTc intervals. Abstr 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy."},{"key":"e_1_3_3_23_2","unstructured":"Savant LI Tao X Anderson J Hesney M Stonier M Lubin S Wang J Hanna GJ Boulton DW. 2015. HIV-1 attachment inhibitor prodrug BMS-663068: interactions with DRV\/r and\/or ETR. Abstr 22nd Conference on Retroviruses and Opportunistic Infections abstr 523."},{"key":"e_1_3_3_24_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2019. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed 12 April 2021."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02251-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02251-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:14:40Z","timestamp":1650374080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02251-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,19]]}},"alternative-id":["10.1128\/aac.02251-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02251-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"2021-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02251-21"}}